Micro‐ to macroalbuminuria · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Micro‐ to normoalbuminuria · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: clinically important change in global state · patients with schizophrenia
1 finding from 1 review
Mental state: clinically important response in mental state BPRS score >30% change · patients with schizophrenia
Clozapine: low dose (150 mg/day to 300 mg/day) showed no clear difference in mental state: clinically important response in mental state BPRS… compared with standard dose (301 mg/day to 600 mg/day) (low certainty).
1 finding from 1 review
Functioning: clinically important change in general functioning, as defined by individual studies · patients with schizophrenia
1 finding from 1 review
Adverse effect: clinically important adverse effect (weight ‐ BMI) · patients with schizophrenia
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · patients with schizophrenia
1 finding from 1 review
Service use: time to hospitalisation · patients with schizophrenia
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review
Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Clobazam (low, medium and high doses) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).
1 finding from 1 review
Seizure freedom · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of mastitis within 6 months postpartum · postpartum breastfeeding women
Breast massage and low frequency pulse treatment may leads to lower incidence of mastitis within 6 months postpartum compared with routine care (low certainty).
1 finding from 1 review
Recurrence of mastitis within 12 months postpartum · postpartum breastfeeding women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Breast abscess within 6 months postpartum · postpartum breastfeeding women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Nipple damage within 6 months postpartum · postpartum breastfeeding women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of any breastfeeding · postpartum breastfeeding women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Breast pain · postpartum breastfeeding women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women with adverse events · postpartum breastfeeding women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found